Table 1.
Demographic and clinical data of the study population
| Healthy | Allrg Rhin | Asm NoEx | Asm Ex | Total | |
|---|---|---|---|---|---|
|
Participants, n (%) |
9 (18.0) |
7 (14.0) |
23 (46.0) |
11 (22.0)a |
50 (100.0) |
|
Female, n (%) |
7 (14.0) |
3 (6.0) |
18 (36.0) |
10 (20.0) |
38 (76.8) |
|
Age; median years (max-min) |
30 (18 to 37) |
31 (20 to 47) |
37 (19 to 66) |
29 (25 to 46) |
32 (18 to 66) |
|
Ethnicity, n (%) |
|
|
|
|
|
| White |
8 (16.0) |
5 (10.0) |
13 (26.0) |
9 (18.0) |
35 (70.0) |
| African American |
0 (0.0) |
1 (2.0) |
4 (8.0) |
1 (2.0) |
6 (12.0) |
| Hispanic |
0 (0.0) |
0 (0.0) |
3 (6.0) |
0 (0.0) |
3 (6.0) |
| Other |
1 (2.0) |
1 (2.0) |
3 (6.0) |
1 (2.0) |
6 (12.0) |
|
Atopic, n (%) |
1 (2.0) |
7 (14.0) |
18 (36.0) |
8 (16.0) |
34 (68.0) |
|
Baseline PC
20
; mean mg/mL (±SD) |
28 (27.1) |
6.7 (3.8) |
4.5 (5.1) |
4.4 (5.2) |
n/a |
|
Baseline FEV1; mean% predicted (±SD) |
98.3 (11.0) |
105.8 (6.7) |
97.8 (16.5) |
91.2 (10.8) |
n/a |
|
Medication, n (%) |
|
|
|
|
|
| Inhaled corticosteroids |
0 (0.0) |
0 (0.0) |
6 (12.0) |
3 (6.0) |
9 (18.0) |
| Inhaled corticosteroids plus long-acting beta agonists |
0 (0.0) |
0 (0.0) |
2 (4.0) |
1 (2.0) |
3 (6.0) |
| Nasal steroids |
0 (0.0) |
0 (0.0) |
6 (12.0) |
3 (6.0) |
9 (18.0) |
|
Respiratory virus identification, n (%) |
|
|
|
|
|
| Human rhinovirus |
5 (10.0) |
1 (2.0) |
9 (18.0) |
3 (6.0) |
18 (36.0) |
| Respiratory syncytial virus |
0 (0.0) |
0 (0.0) |
2 (4.0) |
1 (2.0)b |
3 (6.0) |
| Human coronavirus |
1 (2.0) |
1 (2.0) |
2 (4.0) |
2 (4.0)b |
6 (12.0) |
| Influenza A virus |
0 (0.0) |
1 (2.0) |
1 (2.0) |
0 (0.0) |
2 (4.0) |
| Human parainfluenza virus |
0 (0.0) |
1 (2.0) |
0 (0.0) |
0 (0.0) |
1 (2.0) |
| No detection | 3 (6.0) | 3 (6.0) | 9 (18.0) | 5 (10.0) | 20 (40.0) |
All bracketed values represent percentage of total participants unless otherwise stated. aAmong the Asm Ex group, n = 4 were classified because of increase/start of corticosteroid or need for medical care and n = 7 were classified due to increased symptoms accompanied by either an increase in albuterol (n = 5 out of 7) or a decline in FEV1 (n = 3 out 7) or peak expiratory flow (n = 6 out of 7). bIncludes dual detections. FEV1, forced expiratory volume in 1 s; PC20, provocative concentration of methacholine causing a 20% fall in FEV1; SD, standard deviation.